Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
Authors:
- Corrado CaracòCCCorrado Caracò
- Nicola MozzilloNMNicola Mozzillo
- Ugo MaroneUMUgo Marone
- Ester SimeoneESEster Simeone
- Lucia BenedettoLBLucia Benedetto
- Gianluca Di MontaGMGianluca Di Monta
- Maria Luisa Di CeciliaMCMaria Luisa Di Cecilia
- Gerardo BottiGBGerardo Botti
- Paolo Antonio AsciertoPAPaolo Antonio Ascierto
Open Access
- 1 December 2013
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 564
Abstract
Background: Treatment of early and multiple cutaneous unresectable recurrences is a major therapeutic problem with around 80% of patients relapsing within 5 years. For lesions refractory to elective treatments, electrochemotherapy (ECT) involving electroporation combined with antineoplastic drug treatment appears to be a new potential option. This study was undertaken to analyze the short- and long-term responses of lesions treated with ECT with intravenous injection of bleomycin in melanoma patients with in-transit disease or distant cutaneous metastases. Methods: Between June 2007 and September 2012, 60 patients with relapsed and refractory cutaneous melanoma metastases or in-transit disease underwent 100 courses of ECT with intravenous injection of bleomycin. Response to treatment was evaluated three months after ECT. A long-lasting response was defined as no cutaneous or in-transit relapse after a minimum of six months. Results: Three months after ECT, a complete response was observed in 29 patients (48.4%), a partial response in 23 patients (38.3%) and no change or progressive disease in 8 patients (13.3%). The objective response rate of all treated lesions was 86.6%. Thirteen patients (44.8% of complete responders) experienced a long-lasting response after one ECT session and were disease-free after a mean duration of follow-up of 27.5 months. Conclusions: The favorable outcome obtained in the present study demonstrates that ECT is a reliable, and effective procedure that provides long-term benefit in terms of curative and palliative treatment for unresectable cutaneous lesions without adversely impacting the quality of life of patients.Keywords
This publication has 20 references indexed in Scilit:
- Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanomaJournal of Translational Medicine, 2012
- Electrochemotherapy of Cutaneous Metastases of Melanoma-A Case Series Study and Systematic Review of the EvidenceDermatologic Surgery, 2011
- Electrochemotherapy in Symptomatic Melanoma Skin Metastases: Intraindividual Comparison with Conventional SurgeryDermatologic Surgery, 2010
- Electrochemotherapy with Intravenous Bleomycin in the Local Treatment of Skin Melanoma MetastasesAnnals of Surgical Oncology, 2008
- Electrochemotherapy in treatment of tumoursEuropean Journal of Surgical Oncology, 2008
- Long-term Results of Hyperthermic, Isolated Limb Perfusion for MelanomaAnnals of Surgery, 2007
- ElectrochemotherapyAnnals of Surgery, 2007
- Factors Predicting the Risk of In-Transit Recurrence After Sentinel Lymphonodectomy in Patients With Cutaneous Malignant MelanomaAnnals of Surgical Oncology, 2006
- The Risk of In-Transit Melanoma Metastasis Depends on Tumor Biology and Not the Surgical Approach to Regional Lymph NodesJournal of Clinical Oncology, 2005
- Electroporation: theory and methods, perspectives for drug delivery, gene therapy and researchActa Physiologica Scandinavica, 2003